Kevin Kunzmann

Major advances to biomarkers, targeted therapies and a modernized care team could help IBD specialists achieve a more nuanced care strategy for children.

Though a regimen of steroids and immunosuppressants are well proven, alternative options may be necessary.

New research suggests multiple antibiotic courses may influence levels of the protein zonulin—which in part may indicate a higher risk of celiac disease.

Particularly in children, it's critical that referring physicians keep an awareness for clear symptoms and signs of autoimmune liver disease.

An interview regarding the current impacts of environmental health on food availability, nutrition, and more.

An institution's review of prescriptions in the first year since dupilumab's historic FDA approval for eosinopihlic esophagitis shows patients waited a mean 46 days to initiate the biologic therapy.

A new study seeks to compare the outcomes of biopsies among American children at risk of celiac disease, with European thresholds that would deem such biopsies unnecessary.

Findings from the pivotal phase 3 trial that which supported linaclotide's FDA approval show significant benefit in bowel movement and stool consistency.

The author of the largest clinical trial for pediatric PFIC to date discusses the various benefit maralixibat provides to disease managementr.

A new review and analysis suggests a combination treatment regimen for children in acute liver failure due to autoimmune hepatitis may help them maintain native liver survival.

Pooled phase 3 data presented at NASPGHAN 2023 support the benefit-risk profile of the IBAT inhibtor in treating the rare liver disease.

The COVID-19 pandemic skyrocketed already high rates of alcohol consumption and related liver disease to unprecedented levels. Addiction specialists and hepatologists are still looking for the best path out.

The indication is the first for an antidepressant that selectively targets the serotonin 1A receptor—a regulator of mood and emotion.

A review of Japan post-marketing data support the biosimilar in use for psoriasis, rheumatoid arthritis, Crohn's disease and ulcerative colitis.

The company shared anticipation that their BLA decision for bimekizumab to treat adults with plaque psoriasis will not come before the end of this month.

The potassium-competitive acid blocker drug class is coming to US digestive disease management. How does it fare to standard antacids and PPIs for GERD?

The UT Health infectious disease specialist reviews new vaccine and treatment options, as well as the threat of an RSV-flu-COVID "triple-epidemic" in this winter season.

A new literature review shows that globally, a majority of both men and women with schizophrenia experience some form of sexual dysfunction.

The advisory committee's vote may trigger an FDA decision to remove more than 250 cough medicine products from the market, or require a reformulation of such items.

The agency anticipates the decision to update monovalent formulas of the Pfizer, Moderna, and future COVID-19 vaccines to reflect circulating variants will become an annual practice.

Crinetics announced findings from the PATHFNDR-1 trial showing the investigative oral daily drug may provide patients with the rare disease an alternative from recurring injection therapy.

A cross-sectional analysis of Medicare Part B data spending shows ophthalmologists who received manufacturer funding were less likely to prescribe bevacizumab.

New 3-year analysis shows a significant rate of patients were able to avoid relapse or hospitalization while receiving the long-acting injectable.

A program from the American Oncology Network shows promise to introducing cost-efficient biosimilar substitution opportunities to prescribers and payors.

An analysis from Taiwan suggest immunogenicity differences are limited between biosimilars approved by the FDA and their reference biologic products.

The University of Miami study previews the upcoming phase 3 trial and what the investigative seladelpar may provide patients with primary biliary cholangitis.

The phase 3 seladelpar investigator discusses the current landscape of care available for patients with PBC.

A recently authorized device for autism detection showed promising accuracy in research across US specialty clinics. The lead author shares his thoughts on a new podcast.

In the latest episode of Lungcast, the diagnosis, classifciation and treatment of PE—namely blood clots—is comprehensively dissected by the Lewis Katz School of Medicine clinician and investigator.

An analysis of life expectancy growth since the 1930s suggest more than 50 countries have surpassed the US—with the gap compared to the leading countries widening in that time.